Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Two-arm, Phase 2 Trial

NCT05277480 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05277480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05277480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Two-arm, Phase 2 Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2022
Completion date
November 26, 2023
Enrollment
81 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

drug, effect of drug, toxicity